[{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Clonidine","moa":"Adrenergic receptor alpha-2","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Monopar Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Monopar Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Clonidine","moa":"Adrenergic receptor alpha-2","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BetterLife Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"BetterLife Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Alfasigma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Alfasigma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Alfasigma \/ Undisclosed"},{"orgOrder":0,"company":"Texas Tech University Health Sciences Center, El Paso","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Lubiprostone","moa":"Chloride channel protein 2","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Texas Tech University Health Sciences Center, El Paso","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Texas Tech University Health Sciences Center, El Paso \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"9","companyTruncated":"Texas Tech University Health Sciences Center, El Paso \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Galectin Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"GEORGIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Belapectin","moa":"Galectin-3","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Galectin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galectin Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Galectin Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Danisco","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Probiotic","year":"2012","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Danisco","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Danisco \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Danisco \/ Undisclosed"},{"orgOrder":0,"company":"Sprim Advanced Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2010","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Sprim Advanced Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sprim Advanced Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Sprim Advanced Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Famous Medical Technology","sponsor":"Affiliated Hospital of Nanjing University of Chinese Medicine | Guangdong Provincial Hospital of Traditional Chinese Medicine | Shanghai University of Traditional Chinese Medicine | ShuGuang Hospital | The First Affiliated Hospital, Guangzhou University o","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2018","type":"Inapplicable","leadProduct":"Shenbai","moa":"Immune","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Famous Medical Technology","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Famous Medical Technology \/ Affiliated Hospital of Nanjing University of Chinese Medicine | Guangdong Provincial Hospital of Traditional Chinese Medicine | Shanghai University of Traditional Chinese Medicine | ShuGuang Hospital | The First Affiliated Hospital, Guangzhou University o","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Famous Medical Technology \/ Affiliated Hospital of Nanjing University of Chinese Medicine | Guangdong Provincial Hospital of Traditional Chinese Medicine | Shanghai University of Traditional Chinese Medicine | ShuGuang Hospital | The First Affiliated Hospital, Guangzhou University o"},{"orgOrder":0,"company":"Children's Hospital Medical Center, Cincinnati","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Benralizumab","moa":"Interleukin-5 receptor subunit alpha","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Children's Hospital Medical Center, Cincinnati","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Children's Hospital Medical Center, Cincinnati \/ AstraZeneca","highestDevelopmentStatusID":"9","companyTruncated":"Children's Hospital Medical Center, Cincinnati \/ AstraZeneca"},{"orgOrder":0,"company":"Ritter Pharmaceuticals","sponsor":"Qualigen Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Carbohydrate","year":"2020","type":"Merger","leadProduct":"Galacto-Oligosaccharide","moa":"Lactase","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Ritter Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ritter Pharmaceuticals \/ Qualigen Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"Ritter Pharmaceuticals \/ Qualigen Therapeutics"},{"orgOrder":0,"company":"Temple University","sponsor":"Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Eluxadoline","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Temple University","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Temple University \/ Allergan","highestDevelopmentStatusID":"9","companyTruncated":"Temple University \/ Allergan"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Naltrexone Methobromide","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"TriHealth","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Naloxegol Oxalate","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"TriHealth","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Pill","sponsorNew":"TriHealth \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"TriHealth \/ Undisclosed"},{"orgOrder":0,"company":"Southern Arizona VA Health Care System","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Esomeprazole Magnesium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Southern Arizona VA Health Care System","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Southern Arizona VA Health Care System \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Southern Arizona VA Health Care System \/ Undisclosed"},{"orgOrder":0,"company":"Livzon Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ilaprazole","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Livzon Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Livzon Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Livzon Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Eisai","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Rabeprazole Sodium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Eisai \/ Undisclosed"},{"orgOrder":0,"company":"Eisai","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Rabeprazole Sodium","moa":"antiulcer agents (benzimidazole derivatives)||Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eisai \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Eisai \/ Undisclosed"},{"orgOrder":0,"company":"University of Calgary","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Prucalopride Succinate","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"University of Calgary","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Calgary \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"9","companyTruncated":"University of Calgary \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Allakos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lirentelimab","moa":"Sialic acid-binding Ig-like lectin 8","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allakos \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Allakos \/ Undisclosed"},{"orgOrder":0,"company":"Allakos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lirentelimab","moa":"Sialic acid-binding Ig-like lectin 8","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allakos \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Allakos \/ Undisclosed"},{"orgOrder":0,"company":"Hamilton Health Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Actazin","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Hamilton Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"Hamilton Health Sciences \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Hamilton Health Sciences \/ Undisclosed"},{"orgOrder":0,"company":"BRAINTREE LABS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"BLI801","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"BRAINTREE LABS","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"BRAINTREE LABS \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"BRAINTREE LABS \/ Undisclosed"},{"orgOrder":0,"company":"BRAINTREE LABS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"BLI801","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"BRAINTREE LABS","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"BRAINTREE LABS \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"BRAINTREE LABS \/ Undisclosed"},{"orgOrder":0,"company":"BRAINTREE LABS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"BLI801","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"BRAINTREE LABS","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"BRAINTREE LABS \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"BRAINTREE LABS \/ Undisclosed"},{"orgOrder":0,"company":"BRAINTREE LABS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"BLI801","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"BRAINTREE LABS","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"BRAINTREE LABS \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"BRAINTREE LABS \/ Undisclosed"},{"orgOrder":0,"company":"Gangnam Severance Hospital","sponsor":"Cell Biotech Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Dietary Supplement","year":"2010","type":"Inapplicable","leadProduct":"Colostrum","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Gangnam Severance Hospital","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gangnam Severance Hospital \/ Cell Biotech Co., Ltd.","highestDevelopmentStatusID":"9","companyTruncated":"Gangnam Severance Hospital \/ Cell Biotech Co., Ltd."},{"orgOrder":0,"company":"Oslo University Hospital","sponsor":"South-Eastern Norway Regional Health Authority | University of Oslo","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NORWAY","productType":"Dietary Supplement","year":"2010","type":"Inapplicable","leadProduct":"Gluten Challenge","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Oslo University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oslo University Hospital \/ South-Eastern Norway Regional Health Authority | University of Oslo","highestDevelopmentStatusID":"9","companyTruncated":"Oslo University Hospital \/ South-Eastern Norway Regional Health Authority | University of Oslo"},{"orgOrder":0,"company":"Renew Life Formulas Inc","sponsor":"Sprim Advanced Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2012","type":"Inapplicable","leadProduct":"Multistrain Probiotic","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Renew Life Formulas Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Renew Life Formulas Inc \/ Sprim Advanced Life Sciences","highestDevelopmentStatusID":"9","companyTruncated":"Renew Life Formulas Inc \/ Sprim Advanced Life Sciences"},{"orgOrder":0,"company":"Atlantia Food Clinical Trials","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Natural Fibre","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Atlantia Food Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Atlantia Food Clinical Trials \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Atlantia Food Clinical Trials \/ Undisclosed"},{"orgOrder":0,"company":"Elgan Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"NTRA-9620","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Elgan Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elgan Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Elgan Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Peritech Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"PP110","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Peritech Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Peritech Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Peritech Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Universiti Sains Malaysia","sponsor":"Morinaga Milk Industry Co., LTD","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"MALAYSIA","productType":"Probiotic","year":"2017","type":"Inapplicable","leadProduct":"Probiotics M-63","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Universiti Sains Malaysia","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Sachet","sponsorNew":"Universiti Sains Malaysia \/ Morinaga Milk Industry Co., LTD","highestDevelopmentStatusID":"9","companyTruncated":"Universiti Sains Malaysia \/ Morinaga Milk Industry Co., LTD"},{"orgOrder":0,"company":"Centre for Infectious Disease Research in Zambia","sponsor":"PATH | Christian Medical College, Vellore, India | Children's Hospital Medical Center, Cincinnati | Bharat Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ZAMBIA","productType":"Vaccine","year":"2018","type":"Inapplicable","leadProduct":"Rotavirus Vaccine (Live Attenuated, Oral)","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Centre for Infectious Disease Research in Zambia","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre for Infectious Disease Research in Zambia \/ PATH | Christian Medical College, Vellore, India | Children's Hospital Medical Center, Cincinnati | Bharat Biotech","highestDevelopmentStatusID":"9","companyTruncated":"Centre for Infectious Disease Research in Zambia \/ PATH | Christian Medical College, Vellore, India | Children's Hospital Medical Center, Cincinnati | Bharat Biotech"},{"orgOrder":0,"company":"Sprim Advanced Life Sciences","sponsor":"The National Institute of Probiotics","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Trenev Trio","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Sprim Advanced Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sprim Advanced Life Sciences \/ The National Institute of Probiotics","highestDevelopmentStatusID":"9","companyTruncated":"Sprim Advanced Life Sciences \/ The National Institute of Probiotics"},{"orgOrder":0,"company":"RDD Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Nifedipine","moa":"Voltage-gated L-type calcium channel","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"RDD Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"RDD Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"RDD Pharma \/ Undisclosed"},{"orgOrder":0,"company":"RDD Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Nifedipine","moa":"Voltage-gated L-type calcium channel","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"RDD Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"RDD Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"RDD Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Karen Noblett","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Botulinum Toxin","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Karen Noblett","highestDevelopmentStatusID":"9","companyTruncated":"AbbVie Inc \/ Karen Noblett"},{"orgOrder":0,"company":"Prolacta Bioscience","sponsor":"Thomas Abrahamsson, MD, PhD","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Dietary Supplement","year":"2019","type":"Inapplicable","leadProduct":"H2MF","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Prolacta Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prolacta Bioscience \/ Thomas Abrahamsson, MD, PhD","highestDevelopmentStatusID":"9","companyTruncated":"Prolacta Bioscience \/ Thomas Abrahamsson, MD, PhD"},{"orgOrder":0,"company":"Aphios","sponsor":"NCCIH","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2025","type":"Funding","leadProduct":"Ginger extract","moa":"5-HT3 receptor","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Aphios","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aphios \/ NCCIH","highestDevelopmentStatusID":"9","companyTruncated":"Aphios \/ NCCIH"}]
Find Gastroenterology Drugs in Phase II/III Clinical Development
Details :
Botulinum Toxin is a Protein drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Non-relaxing Puborectalis Syndrome.
Details :
The grant assures’ Aphios’ continuing ability to advance the development of Zindol, a novel botanical drug candidate derived from ginger for the treatment of CINV.
Details :
Validive® (clonidine hydrochloride) is a novel mucobuccal tablet (MBT) formulation of clonidine. The mucobuccal tablet provides for prolonged local delivery of clonidine to the regions of oral mucosal radiation damage in oropharyngeal cancer (OPC) patie...
Details :
Amisulpride is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Postoperative Nausea and Vomiting.
Details :
The trial, which began earlier this year in the US, is evaluating Validive® (clonidine HCl MBT) to prevent the onset of severe oral mucositis (SOM) in oropharyngeal cancer (OPC) patients treated with chemoradiotherapy.
Details :
The VOICE study evaluates Validive® for the prevention of severe oral mucositis (SOM) in oropharyngeal cancer patients. SOM results from the chemoradiation used to treat oropharyngeal cancer (OPC).
Details :
This analysis provided the rationale for the design of Monopar’s Phase 2b/3 VOICE trial, which is open and accruing oropharyngeal cancer patients in the US.
Details :
Validive (Clonidine HCl) is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Mucositis.
Details :
Patent provide claims covering “Clonidine and/or clonidine derivatives for use in the prevention and/or treatment of adverse side effects of chemotherapy”.
Reset All
